Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

4.9K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel quinine derivative as a PIM-1 kinase inhibitor induces apoptosis via mitochondrial depolarization with selective cytotoxicity in acute lymphoblastic leukemia cells.

Frontiers in pharmacology·2026
Same author

Discovery of Two Novel Pyrazole Derivatives as Anticancer Agents Targeting Tubulin Polymerization and MAPK Signaling Pathways.

Oncology research·2026
Same author

Novel 4-quinolone derivative inflicted cytotoxicity via intrinsic apoptotic pathway activation on human metastatic triple-negative breast cancer cells.

Bioorganic chemistry·2025
Same author

RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family of <i>RAS</i> Genes and Ras Proteins in Housekeeping and Tumorigenesis.

Biology·2025
Same author

Design, synthesis and anticancer evaluation of novel hydrazide-2-oxindole analogues as GSK-3β kinase inhibitors.

RSC advances·2025
Same author

Investigation of Anti-Cancer Properties of Novel Curcuminoids in Leukemic Cells and Dalton Lymphoma Ascites Model.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jan 9, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.9K

Functional Characterization of VS-186B, a Novel HDAC Inhibitor with Anticancer Activity.

Laura A Sanchez-Michael1, Vijayalakshmi Sudarshan2,3,4, Allison Elias1

  • 1Department of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA.

International Journal of Molecular Sciences
|December 11, 2025
PubMed
Summary

A new compound, VS-186B, effectively targets cancer cells by inhibiting histone deacetylases (HDACs), inducing apoptosis. This novel epigenetic therapy shows promise for leukemia and lymphoma treatment with minimal toxicity to healthy cells.

Keywords:
HDAC inhibitorJurkatVorinostatanti-cancerapoptosiscurcumincytotoxicityleukemiaselectivity

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.9K
Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

9.5K

Related Experiment Videos

Last Updated: Jan 9, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.9K
Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.9K
Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

9.5K

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Histone acetylation/deacetylation regulates gene expression and is crucial in cancer development and therapy resistance.
  • Histone deacetylases (HDACs) overexpression silences tumor suppressors, promoting cancer cell proliferation.
  • Epigenetic alterations enable tumors to evade treatment and develop resistance.

Purpose of the Study:

  • To identify novel compounds selectively targeting cancer cells with reduced toxicity.
  • To evaluate a series of novel histone deacetylase inhibitors (HDACis) for anticancer potential.

Main Methods:

  • Differential Nuclear Staining (DNS) assay, flow cytometry, and HDAC inhibition assays were used.
  • Cytotoxicity, selectivity, and cell death mechanisms were assessed.
  • Connectivity Map (CMap) analysis and enzymatic assays confirmed HDAC inhibition.

Main Results:

  • VS-186B demonstrated superior cytotoxicity and selectivity (Selective Cytotoxicity Index) against Jurkat T-cell leukemia.
  • VS-186B induced apoptosis via Annexin V-FITC, ROS, JC-1, and Caspase-3/7 pathways.
  • VS-186B inhibited Class I and II HDACs dose-dependently and showed gene expression similarity to known HDACis.

Conclusions:

  • VS-186B is a potent and selective HDAC inhibitor inducing apoptosis in cancer cells.
  • VS-186B exhibits minimal toxicity to non-cancerous cell lines, suggesting therapeutic potential.
  • VS-186B warrants further investigation as an epigenetic treatment for leukemia and lymphoma.